Cargando…

Drug-Associated Gastropathy: Diagnostic Criteria

Drugs are widely used to treat different diseases in modern medicine, but they are often associated with adverse events. Those located in the gastrointestinal tract are common and often mild, but they can be serious or life-threatening and determine the continuation of treatment. The stomach is ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordin, Dmitry S., Livzan, Maria A., Gaus, Olga V., Mozgovoi, Sergei I., Lanas, Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341309/
https://www.ncbi.nlm.nih.gov/pubmed/37443618
http://dx.doi.org/10.3390/diagnostics13132220
_version_ 1785072231778353152
author Bordin, Dmitry S.
Livzan, Maria A.
Gaus, Olga V.
Mozgovoi, Sergei I.
Lanas, Angel
author_facet Bordin, Dmitry S.
Livzan, Maria A.
Gaus, Olga V.
Mozgovoi, Sergei I.
Lanas, Angel
author_sort Bordin, Dmitry S.
collection PubMed
description Drugs are widely used to treat different diseases in modern medicine, but they are often associated with adverse events. Those located in the gastrointestinal tract are common and often mild, but they can be serious or life-threatening and determine the continuation of treatment. The stomach is often affected not only by drugs taken orally but also by those administered parenterally. Here, we review the mechanisms of damage, risk factors and specific endoscopic, histopathological and clinical features of those drugs more often involved in gastric damage, namely NSAIDs, aspirin, anticoagulants, glucocorticosteroids, anticancer drugs, oral iron preparations and proton pump inhibitors. NSAID- and aspirin-associated forms of gastric damage are widely studied and have specific features, although they are often hidden by the coexistence of Helicobacter pylori infection. However, the damaging effect of anticoagulants and corticosteroids or oral iron therapy on the gastric mucosa is controversial. At the same time, the increased use of new antineoplastic drugs, such as checkpoint inhibitors, has opened up a new area of gastrointestinal damage that will be seen more frequently in the near future. We conclude that there is a need to expand and understand drug-induced gastrointestinal damage to prevent and recognize drug-associated gastropathy in a timely manner.
format Online
Article
Text
id pubmed-10341309
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103413092023-07-14 Drug-Associated Gastropathy: Diagnostic Criteria Bordin, Dmitry S. Livzan, Maria A. Gaus, Olga V. Mozgovoi, Sergei I. Lanas, Angel Diagnostics (Basel) Review Drugs are widely used to treat different diseases in modern medicine, but they are often associated with adverse events. Those located in the gastrointestinal tract are common and often mild, but they can be serious or life-threatening and determine the continuation of treatment. The stomach is often affected not only by drugs taken orally but also by those administered parenterally. Here, we review the mechanisms of damage, risk factors and specific endoscopic, histopathological and clinical features of those drugs more often involved in gastric damage, namely NSAIDs, aspirin, anticoagulants, glucocorticosteroids, anticancer drugs, oral iron preparations and proton pump inhibitors. NSAID- and aspirin-associated forms of gastric damage are widely studied and have specific features, although they are often hidden by the coexistence of Helicobacter pylori infection. However, the damaging effect of anticoagulants and corticosteroids or oral iron therapy on the gastric mucosa is controversial. At the same time, the increased use of new antineoplastic drugs, such as checkpoint inhibitors, has opened up a new area of gastrointestinal damage that will be seen more frequently in the near future. We conclude that there is a need to expand and understand drug-induced gastrointestinal damage to prevent and recognize drug-associated gastropathy in a timely manner. MDPI 2023-06-29 /pmc/articles/PMC10341309/ /pubmed/37443618 http://dx.doi.org/10.3390/diagnostics13132220 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bordin, Dmitry S.
Livzan, Maria A.
Gaus, Olga V.
Mozgovoi, Sergei I.
Lanas, Angel
Drug-Associated Gastropathy: Diagnostic Criteria
title Drug-Associated Gastropathy: Diagnostic Criteria
title_full Drug-Associated Gastropathy: Diagnostic Criteria
title_fullStr Drug-Associated Gastropathy: Diagnostic Criteria
title_full_unstemmed Drug-Associated Gastropathy: Diagnostic Criteria
title_short Drug-Associated Gastropathy: Diagnostic Criteria
title_sort drug-associated gastropathy: diagnostic criteria
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341309/
https://www.ncbi.nlm.nih.gov/pubmed/37443618
http://dx.doi.org/10.3390/diagnostics13132220
work_keys_str_mv AT bordindmitrys drugassociatedgastropathydiagnosticcriteria
AT livzanmariaa drugassociatedgastropathydiagnosticcriteria
AT gausolgav drugassociatedgastropathydiagnosticcriteria
AT mozgovoisergeii drugassociatedgastropathydiagnosticcriteria
AT lanasangel drugassociatedgastropathydiagnosticcriteria